Document is current
Any future updates will be listed below
-
Authors
Bando, Hideaki https://orcid.org/0000-0001-5041-2765
Naito, Yoichi
Yamada, Tomoyuki
Fujisawa, Takao
Imai, Mitsuho
Sakamoto, Yasutoshi
Saigusa, Yusuke
Yamamoto, Kouji
Tomioka, Yutaka
Takeshita, Nobuyoshi
Sunami, Kuniko
Futamura, Megumi
Notake, Chiemi
Aoki, Satoko
Okano, Kazunori
Yoshino, Takayuki
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP23he0122034)
New Energy and Industrial Technology Development Organization (JPNP14012)
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 13 December 2024
First Online: 23 December 2024
Declarations
:
: Hideaki Bando received research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly Japan. Yoichi Naito received research funding from ABBVIE, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, and Baye, and honoraria from AstraZeneca, Eisai, Ono, Guardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, PDR Pharma, Nihon Kayaku, Taiho, Bristol Mayers, Bayer, and Dai@@. Tomoyuki Yamada is an employee of Genomedia Inc. Takao Fujisawa received honoraria for lectures from Amelieff Co., Ltd. Mitsuho Imai is an advisory for Sumitomo Co., Ltd. and Exact Sciences Corporation, speakers’ bureau from Chugai Pharmaceutical Co., Ltd., and received research funding from Merck Sharp and Dohme, Inc. Yasutoshi Sakamoto and Yusuke Saigusa declare no conflicts of interest. Koji Yamamoto received research funding from Chugai Pharmaceutical and honoraria from FUJIFILM, Toyama, Delta-Fly Pharma, Takeda, CMIC, CM Plus, DAIICHI SANKYO, AstraZeneca, and TME. Yutaka Tomioka and Nobuyoshi Takeshita report no conflict of interest. Kuniko Sunami received research funding from Sysmex. Megumi Futamura and Chiemi Notake report no conflicts of interest. Satoko Aoki and Kazunori Okano are employees of Genomedia, Inc. Takayuki Yoshino received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, and MSD and research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Amgen, Parexel International, MSD, Daiichi Sankyo, Pfizer, Genomedia, Sysmex, Nihon Boehringer Ingelheim, and Sanofi.
: The trial protocol was approved by the institutional review board of each participating site before study initiation (2024-230). The study will be conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.
